142 related articles for article (PubMed ID: 18925690)
1. Rare diseases in Croatia--lesson learned from Anderson-Fabry disease.
Mrsić M; Nola M
Croat Med J; 2008 Oct; 49(5):579-81. PubMed ID: 18925690
[No Abstract] [Full Text] [Related]
2. Diagnostic challenges and new therapies for rare lysosomal storage diseases.
Hesselgrave B
Case Manager; 2003; 14(6):48-52. PubMed ID: 14618149
[No Abstract] [Full Text] [Related]
3. [CME. Fabry disease: rare but not to be missed].
Steinack C; Gaspert A; Kovacs R; Nowak A
Praxis (Bern 1994); 2015 Jul; 104(14):719-29. PubMed ID: 26135721
[No Abstract] [Full Text] [Related]
4. Enzyme replacement in Anderson-Fabry disease.
Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
[No Abstract] [Full Text] [Related]
5. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
Basic-Jukic N; Kes P; Mokos I; Coric M
Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
[No Abstract] [Full Text] [Related]
6. [What is new in Fabry disease?].
Lidove O
Rev Med Interne; 2007 Dec; 28 Suppl 4():S296-7. PubMed ID: 17964003
[No Abstract] [Full Text] [Related]
7. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
[TBL] [Abstract][Full Text] [Related]
8. Pediatrics: implementing the promise of early intervention for Fabry disease.
Raas-Rothschild A
Clin Ther; 2007; 29 Suppl A():S6. PubMed ID: 17580239
[No Abstract] [Full Text] [Related]
9. [Fabry disease--guidelines for diagnosis and management of adult patients].
Merkler M; Pećin I; Simić I; Muacević-Katanec D; Sućur N; Reiner Z
Lijec Vjesn; 2014; 136(5-6):133-5. PubMed ID: 25154181
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease in an oligosymptomatic male.
Altarescu G; Elstein D
Isr Med Assoc J; 2011 Mar; 13(3):191-2. PubMed ID: 21608346
[No Abstract] [Full Text] [Related]
11. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.
Moore DF; Ries M; Forget EL; Schiffmann R
Pharmacoeconomics; 2007; 25(3):201-8. PubMed ID: 17335306
[TBL] [Abstract][Full Text] [Related]
12. Anderson-Fabry disease: enzyme replacement therapy.
Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
[No Abstract] [Full Text] [Related]
13. [Fabry disease].
Jakubowska E; Ryba M; Hruby Z
Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
[TBL] [Abstract][Full Text] [Related]
14. Enzyme-replacement therapy for Anderson-Fabry disease.
Pastores GM; Thadhani R
Lancet; 2001 Aug; 358(9282):601-3. PubMed ID: 11530143
[No Abstract] [Full Text] [Related]
15. [Recent therapeutics for Fabry disease].
Etou Y
Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):875-82. PubMed ID: 19469078
[No Abstract] [Full Text] [Related]
16. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
Wanner C
Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
[No Abstract] [Full Text] [Related]
18. [Fabry disease: new clinical research--current therapeutic perspectives].
Beck M
Wien Klin Wochenschr; 2003 Apr; 115(7-8):215-7. PubMed ID: 12778772
[No Abstract] [Full Text] [Related]
19. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
Ramaswami U
Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
